Vascular Biogenics Ltd expected to post a loss of 11  cents a share - Earnings Preview

Notable Labs

13/05/2022 14:23

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 17. 
    * The Modiin Israel-based   company is expected to report  a
8.1% increase in revenue to $200 thousand from $185 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vascular Biogenics
Ltd is
for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of 12 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5​, above​ its last closing price of $1.26.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.08       -0.09      -0.12     Missed  -37.1
 Sep. 30 2021  -0.11       -0.11      -0.09     Beat    16.3
 Jun. 30 2021  -0.11       -0.11      -0.12     Missed  -11.6​
 Mar. 31 2021  -0.13       -0.13      -0.12     Beat    7.7
 ​​Dec.                    -0.14      -0.15     Missed  -7.1
 31 2020                                                
 Sep. 30 2020  -0.14       -0.13      -0.12     Beat    10.2​
 Jun. 30 2020  -0.14       -0.14      -0.14     Met     -1.4
 Mar. 31 2020  -0.17       -0.17      -0.15     Beat    9.4
 This summary was machine generated May 13 at 13:23 GMT.  All
figures in US dollars  unless otherwise stated